CN110997666A - N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法 - Google Patents

N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法 Download PDF

Info

Publication number
CN110997666A
CN110997666A CN201780093736.XA CN201780093736A CN110997666A CN 110997666 A CN110997666 A CN 110997666A CN 201780093736 A CN201780093736 A CN 201780093736A CN 110997666 A CN110997666 A CN 110997666A
Authority
CN
China
Prior art keywords
palbociclib
formate
acid
formyl
chloroformate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780093736.XA
Other languages
English (en)
Inventor
林金生
朱文泉
胡李斌
曾令清
付稳
李敏
王志云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Huahai Pharmaceutical Co Ltd
Original Assignee
Zhejiang Huahai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Huahai Pharmaceutical Co Ltd filed Critical Zhejiang Huahai Pharmaceutical Co Ltd
Publication of CN110997666A publication Critical patent/CN110997666A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种帕博西尼固体制剂中的降解杂质N‑甲酰基帕博西尼、其制备方法，及其在帕博西尼固体制剂处方研究、杂质检测中的应用。还提供了一种稳定化的帕博西尼固体制剂及其制备方法。N‑甲酰基帕博西尼制备方法，产物收率可达50％以上，纯度可达90％以上，其具有工艺简单，产物纯度高、生产周期较短、适合实验室快速制备及能大规模制备等优点。获得的帕博西尼固体制剂其稳定性提高，在60℃，75％相对湿度条件下放置10天后，帕博西尼固体制剂中N‑甲酰基帕博西尼杂质也未见增长。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201780093736.XA 2017-09-19 2017-09-19 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法 Pending CN110997666A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/102219 WO2019056163A1 (zh) 2017-09-19 2017-09-19 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法

Publications (1)

Publication Number Publication Date
CN110997666A true CN110997666A (zh) 2020-04-10

Family

ID=65809441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780093736.XA Pending CN110997666A (zh) 2017-09-19 2017-09-19 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法

Country Status (2)

Country Link
CN (1) CN110997666A (zh)
WO (1) WO2019056163A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274493A (zh) * 2020-11-18 2021-01-29 石药集团中奇制药技术（石家庄）有限公司 一种哌柏西利胶囊的制备方法
US11464779B2 (en) 2016-03-29 2022-10-11 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11471418B2 (en) 2020-09-29 2022-10-18 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of amorphous solid dispersions and methods of preparation thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112961152B (zh) * 2020-02-26 2021-11-12 北京新康哌森医药科技有限公司 一种帕布昔利布杂质的合成方法
CN111362938A (zh) * 2020-04-14 2020-07-03 北京鑫开元医药科技有限公司 一种帕布昔利布杂质、其制备方法及用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN105748435A (zh) * 2016-04-21 2016-07-13 石家庄海瑞药物科技有限公司 一种帕布昔利布药物组合物及其制备方法
CN106667952A (zh) * 2016-12-12 2017-05-17 河南润弘制药股份有限公司 一种帕布昔利布药物组合物及其制备方法
CN107666914A (zh) * 2015-06-04 2018-02-06 辉瑞公司 帕博西尼的固体剂型
CN111239299A (zh) * 2020-03-30 2020-06-05 重庆三圣实业股份有限公司 一种分离测定帕博西尼及其杂质的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
CN105213322A (zh) * 2015-10-30 2016-01-06 南京正大天晴制药有限公司 一种干法制粒工艺制备的药物组合物
CN106924210A (zh) * 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107666914A (zh) * 2015-06-04 2018-02-06 辉瑞公司 帕博西尼的固体剂型
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN105748435A (zh) * 2016-04-21 2016-07-13 石家庄海瑞药物科技有限公司 一种帕布昔利布药物组合物及其制备方法
CN106667952A (zh) * 2016-12-12 2017-05-17 河南润弘制药股份有限公司 一种帕布昔利布药物组合物及其制备方法
CN111239299A (zh) * 2020-03-30 2020-06-05 重庆三圣实业股份有限公司 一种分离测定帕博西尼及其杂质的方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464779B2 (en) 2016-03-29 2022-10-11 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11471418B2 (en) 2020-09-29 2022-10-18 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of amorphous solid dispersions and methods of preparation thereof
CN112274493A (zh) * 2020-11-18 2021-01-29 石药集团中奇制药技术（石家庄）有限公司 一种哌柏西利胶囊的制备方法

Also Published As

Publication number Publication date
WO2019056163A1 (zh) 2019-03-28

Similar Documents

Publication Publication Date Title
CN110997666A (zh) N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
KR101593768B1 (ko) 토파시티닙의 결정질 형태 및 비결정질 형태, 및 토파시티닙 및 침투 증진제를 포함하는 제약 조성물
EP3122753A2 (en) Ibrutinib solid forms and production process therefor
CN102791719A (zh) 二胺衍生物的晶体及其制备方法
EP3057965B1 (en) Salt and crystal forms of plk-4 inhibitor
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
EP2880019B1 (en) Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
US11572365B2 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
EP3553058A1 (en) Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof
CN113651770B (zh) 一种依帕司他晶型及其制备方法和应用
CN110452248B (zh) 一种新颖倍半萜化合物及其制备方法与应用
CN107434794B (zh) 一种氢溴酸沃替西汀降解产物的制备方法及应用
US11261196B2 (en) Salt serving as AKT inhibitor and crystal thereof
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
EP3736273A1 (en) Novel crystal form of acalabrutinib and preparation method and use thereof
AU2021106179A4 (en) New crystalline form of epalrestat as well as preparation method and application thereof
EP3971175A1 (en) Crystal form of quinazolinone compound and preparation method therefor
CN111032635B (zh) N-甲酰基沃替西汀及其制备方法和沃替西汀的固体制剂
CN111484495A (zh) 含二氢蝶啶二酮骨架衍生物的制备方法和用途
CN114644616B (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
EP4049999A1 (en) Crystal form of hypoxia-inducible factor-prolyl hydroxylase inhibitor
CN114573591B (zh) 一种取代的吡咯并嘧啶化合物及其应用
BUCHI REDDY et al. Identification and characterization of potential impurities in raloxifene hydrochloride
EP4130004A1 (en) Salt and crystalline forms of fgfr4 inhibitor and uses thereof
EP4056182A1 (en) Crystal form of aprocitentan, preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination